Cellular Strategies for Separating GvHD from GvL in Haploidentical Transplantation

Mauro Di Ianni; Carmine Liberatore; Nicole Santoro; Paola Ranalli; Francesco Guardalupi; Giulia Corradi; Ida Villanova; Barbara Di Francesco; Stefano Lattanzio; Cecilia Passeri; Paola Lanuti; Patrizia Accorsi

doi:10.3390/cells13020134

Cellular Strategies for Separating GvHD from GvL in Haploidentical Transplantation

Cells. 2024 Jan 11;13(2):134. doi: 10.3390/cells13020134.

Authors

Mauro Di Ianni^{1

2

3}, Carmine Liberatore¹, Nicole Santoro¹, Paola Ranalli^{1

2

3}, Francesco Guardalupi^{2

3}, Giulia Corradi^{2

3}, Ida Villanova⁴, Barbara Di Francesco⁴, Stefano Lattanzio^{2

3}, Cecilia Passeri⁴, Paola Lanuti^{2

3}, Patrizia Accorsi⁴

Affiliations

¹ Hematology Unit, Pescara Hospital, 65124 Pescara, Italy.
² Department of Medicine and Aging Sciences, University of Chieti-Pescara, 66100 Chieti, Italy.
³ Center for Advanced Studies and Technology (CAST), University of Chieti-Pescara, 66100 Chieti, Italy.
⁴ Blood Bank Unit, Pescara Hospital, 65124 Pescara, Italy.

Abstract

GvHD still remains, despite the continuous improvement of transplantation platforms, a fearful complication of transplantation from allogeneic donors. Being able to separate GvHD from GvL represents the greatest challenge in the allogeneic transplant setting. This may be possible through continuous improvement of cell therapy techniques. In this review, current cell therapies are taken into consideration, which are based on the use of TCR alpha/beta depletion, CD45RA depletion, T regulatory cell enrichment, NK-cell-based immunotherapies, and suicide gene therapies in order to prevent GvHD and maximally amplify the GvL effect in the setting of haploidentical transplantation.

Keywords: CD45RA; GvHD; GvL; NK; TCR alpha-beta; Tregs; immunotherapies; suicide gene.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Cell- and Tissue-Based Therapy*
Fear
Humans
Immunotherapy
Killer Cells, Natural
Transplantation, Haploidentical*

Grants and funding

This work was supported by Italian Ministry of Health (PNC-E3-2022-23683269 PNC-HLS-TA) and by the Associazione Italiana contro le Leucemie-Linfomi e Mieloma (AIL), L’Aquila Section, Italy.